Nutra Pharma Corporation (OTC: NPHC) is a biotechnology
company specializing in the acquisition, licensing and commercialization of
pharmaceutical products and technologies for the management of neurological
disorders, cancer, autoimmune and infectious diseases. The company’s product
portfolio includes Cobroxin, the first over-the-counter pain reliever clinically
proven to treat moderate to severe chronic pain, and Nyloxin, the only
non-narcotic and non-addictive treatment for severe pain. Both products were
developed by Nutra Pharma’s wholly-owned drug discovery subsidiary,
ReceptoPharm.
Currently, ReceptoPharm is developing proprietary
therapeutic protein products for the prevention and treatment of viral and
neurological diseases by leveraging the specialized receptor-binding proteins
found in nature, particularly those found in cobra venom. The company’s leading
drug candidates, RPI-MN and RPI-78M, are being developed for the treatment of
HIV and multiple sclerosis, respectively. By leveraging a proprietary chemical
process, ReceptoPharm is able to create drugs that possess a host of desirable
properties – including lack of toxicity (which eliminates the threat of
overdosing), extended shelf life and total absence of serious adverse side
effects.
Earlier this month, Nutra Pharma took a significant step in
the development of RPI-78M when it announced that it had applied for an orphan
drug designation from the U.S. Food and Drug Administration for the treatment
of Myasthenia Gravis (MG). If received, this would be the company’s second
orphan drug designation approved in recent weeks. In September, Nutra Pharma
was granted the designation for the treatment of Pediatric Multiple Sclerosis
(MS).
Orphan drug designations are designed to encourage the
development of drugs which may provide significant benefits to patients
suffering from rare diseases. For pharmaceutical companies, the program offers
a seven-year period of market exclusivity, as well as tax credits and, in many
cases, grant funding to cover a portion of clinical research costs.
“We have been clear over the last year that we would be
moving our drug platforms forward,” Rik J. Deitsch, chairman and chief
executive officer of Nutra Pharma, stated in a news release. “This includes our
work in Pediatric Multiple Sclerosis as well as additional potential orphan
designations for our therapeutic pipeline.”
Although MS most commonly occurs in adults, it also effects
an estimated 10,000 children in the U.S., according to the National Multiple
Sclerosis Society. There are currently no approved treatments for pediatric MS.
Instead, FDA-approved self-injectable disease-modifying therapies developed for
use in adults are often used ‘off-label’ in children. Large clinical trials are
still needed to assess the treatment efficacy of these therapies in the
pediatric population, making a therapeutic designed and tested specifically to
treat pediatric MS a potential game changer moving forward.
For more information on the company, visit
www.NutraPharma.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment